RAPT Therapeutics Inc (RAPT)
4.135
-0.11
(-2.59%)
USD |
NASDAQ |
May 16, 16:00
4.135
0.00 (0.00%)
After-Hours: 20:00
RAPT Therapeutics Cash from Financing (TTM): 10.37M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.37M |
| December 31, 2023 | 1.447M |
| September 30, 2023 | 76.35M |
| June 30, 2023 | 81.49M |
| March 31, 2023 | 131.16M |
| December 31, 2022 | 131.18M |
| September 30, 2022 | 56.42M |
| June 30, 2022 | 51.64M |
| March 31, 2022 | 140.31M |
| December 31, 2021 | 141.48M |
| September 30, 2021 | 145.44M |
| Date | Value |
|---|---|
| June 30, 2021 | 145.13M |
| March 31, 2021 | 6.89M |
| December 31, 2020 | 75.46M |
| September 30, 2020 | 105.64M |
| June 30, 2020 | 106.14M |
| March 31, 2020 | 112.76M |
| December 31, 2019 | 49.90M |
| September 30, 2019 | 37.78M |
| June 30, 2019 | 37.18M |
| March 31, 2019 | 59.66M |
| December 31, 2018 | 52.73M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.447M
Minimum
Dec 2023
145.44M
Maximum
Sep 2021
82.21M
Average
78.92M
Median
Cash from Financing (TTM) Benchmarks
| Emergent BioSolutions Inc | -484.50M |
| Avinger Inc | 5.112M |
| Tonix Pharmaceuticals Holding Corp | 36.52M |
| Skye Bioscience Inc | 102.14M |
| Axsome Therapeutics Inc | 278.26M |